Granted Patent B2

US 11,332,507 · App. 16/128,008 · Granted May 17, 2022

Inventors: Justin Scheer (Ridgefield, CT); Wenjun Ouyang (Foster City, CA); Richard Vandlen (Hillsborough, CA); Philip E. Hass (Moss Beach, CA); Eric Gary Stefanich (Emerald Hills, CA); Xiaoting Wang (Berkeley, CA)

Assignee: Genentech, Inc.

C07K14/54A61K38/20A61K47/38C07K16/2866A61K38/00C07K2319/30

Abstract

Claims (13)

1. An interleukin (IL)-22 Fc fusion protein that binds to IL-22 receptor, the IL-22 Fc fusion protein comprising an IL-22 polypeptide linked to an IgG4 Fc region by a linker, wherein the Fc region is not glycosylated, wherein the amino acid residue at position 299 as in the EU index of the Fc region is Ala, Gly, or Val, and wherein the linker consists of the amino acid sequence of RVESKYGPP (SEQ ID NO:44).

2. The IL-22 Fc fusion protein of claim 1 , wherein the IL-22 polypeptide is a human IL-22 polypeptide.

3. The IL-22 Fc fusion protein of claim 1 , wherein the IL-22 polypeptide comprises the amino acid sequence of SEQ ID NO:4.

4. The IL-22 Fc fusion protein of claim 1 , wherein the IL-22 receptor is a human IL-22 receptor.

5. The IL-22 Fc fusion protein of claim 1 , wherein the Fc region comprises a hinge region comprising the amino acid sequence of CPPCP (SEQ ID NO:31).

6. The IL-22 Fc fusion protein of claim 1 , wherein the IL-22 fusion protein is a dimeric IL-22 Fc fusion protein.

7. The IL-22 Fc fusion protein of claim 1 , wherein the IL-22 fusion protein is a monomeric IL-22 Fc fusion protein.

8. The IL-22 Fc fusion protein of claim 1 , wherein the IL-22 Fc fusion protein is produced by a process comprising the step of culturing a host cell capable of expressing the IL-22 Fc fusion protein under conditions suitable for expression of the IL-22 Fc fusion protein.

9. The IL-22 Fc fusion protein of claim 8 , wherein the process further comprises the step of obtaining the IL-22 Fc fusion protein from the cell culture or culture medium.

10. The IL-22 Fc fusion protein of claim 8 , wherein the host cell is a Chinese hamster ovary (CHO) cell.

11. A pharmaceutical composition comprising the IL-22 Fc fusion protein of claim 1 and at least one pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11 , wherein the IL-22 Fc fusion protein is produced in a CHO cell.

13. The pharmaceutical composition of claim 11 , further comprising an additional therapeutic agent.

Continuity (9)